In a report released yesterday, Craig Bijou from Cantor Fitzgerald maintained a Buy rating on Cerus Corp (CERS), with a price target of $9. The company’s shares closed on Friday at $5.54.
Bijou observed:
“: We hosted investor meetings with CERS’s management late last week. We think the pressure on the stock in the latter half of last week was an overreaction and does not give CERS credit for its commercial execution and near- term catalysts.”
According to TipRanks.com, Bijou is a 3-star analyst with an average return of 4.0% and a 52.4% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Ra Medical Systems Inc, and Integra Lifesciences.
Currently, the analyst consensus on Cerus Corp is a Moderate Buy with an average price target of $9.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.05 and a one-year low of $4.71. Currently, Cerus Corp has an average volume of 815.9K.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. Last month, William Mariner Greenman, the President & CEO of CERS bought 100 shares for a total of $106.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The company produces blood system for platelets and plasma. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
